comscoreResearch Highlights From the 2015 San Antonio Breast Cancer Symposium

Research Highlights From the 2015 San Antonio Breast Cancer Symposium

Brian Wojciechowski, MD, talks about some of the studies presented at the San Antonio Breast Cancer Symposium.
Oct 19, 2016

In this podcast, Dr. Brian Wojciechowski talks about four studies that were presented at the 2015 San Antonio Breast Cancer Symposium, December 8-12, including studies that offer encouraging news about treatment for women diagnosed with triple-negative disease and metastatic, HER2-positive breast cancer.

Listen to the podcast to hear Dr. Wojciechowski explain:

  • what luminal A breast cancer is and why women diagnosed with this subtype didn’t seem to benefit from chemotherapy after surgery

  • why adding carboplatin to a standard chemotherapy before surgery for triple-negative breast cancer improved pathologic complete response rates and what this means for women with triple-negative disease

  • why postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who are taking an aromatase inhibitor and have experienced bone loss might want to consider taking the targeted therapy denosumab

  • results showing that Kadcyla improves overall survival in women diagnosed with metastatic, HER2-positive breast cancer that has stopped responding to Herceptin and Tykerb

About the guest
Brian Wojciechowski headshot
Brian Wojciechowski, MD

Dr. Wojo is a medical oncologist outside of Philadelphia, PA, with Crozer Health. His research has been presented at the San Antonio Breast Cancer Symposium, and he is a speaker on medical ethics and the biology of cancer. Dr. Wojo sees cancer as a scientifically complex disease with psychological, social, and spiritual dimensions.

— Last updated on June 29, 2022, 2:46 PM


This content made possible by Lilly Oncology.

Support to produce more content like this

Your donation goes directly to what you read, hear, and see on